Experienced in Subarachnoid Hemorrhage

Ricardo C. Reisin

Buenos Aires, C, AR 
Experienced in Subarachnoid Hemorrhage
Buenos Aires, C, AR 
OverviewLocationsClinical Research

Overview

Ricardo Reisin practices in Buenos Aires, Argentina. Mr. Reisin is rated as an Experienced expert by MediFind in the treatment of Subarachnoid Hemorrhage. His top areas of expertise are Fabry Disease, Guillain-Barre Syndrome, Primary Lateral Sclerosis, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease).

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Subarachnoid Hemorrhage.

Gender
Male

Locations

Buenos Aires, C, Argentina
Other Locations
B, Argentina
Mar Del Plata, B, Argentina
Argentina, G, Argentina

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
International GBS Outcome Study (IGOS): a Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS).
Enrollment Status: Completed
Publish Date: December 12, 2024
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Biological
Study Drug: HYQVIA
Study Phase: Phase 3
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
A Phase 3, Open-label Study to Evaluate the Efficacy and Safety of REPLAGAL® in Treatment-naïve Subjects With Fabry Disease
Enrollment Status: Terminated
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Replagal
Study Phase: Phase 3
View 2 Less Clinical Trials

70 Total Publications

Marcus Gunn syndrome: a released phylogenetic old reflex?
Marcus Gunn syndrome: a released phylogenetic old reflex?
Journal: Medicina
Published: June 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Reisin's expertise for a condition
ConditionClose
    View All 35 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile